The Role of Matrix Metalloproteinase9 (MMP9) in Endometriosis: Peran Matriks MetalloproteinaseÂ­9 (MMPÂ­9) pada Endometriosi by Amalia, Amalia et al.
Research  Article
The Role of Matrix Metalloproteinase­9 (MMP­9)  in Endometriosis
Peran Matriks Metalloproteinase­9 (MMP­9) pada Endometriosis
Amalia, Nusratuddin Abdullah, Umar Malinta
Department of Obstetrics and Gynecology
Faculty of Medicine Universitas Hasanuddin/
Dr. Wahidin Sudirohusodo Hospital
Makassar
INTRODUCTION
Endometriosis is a chronic gynecological disorder
that is dependent on estrogen levels (estrogen-
dependent). It is usually associated with pelvic pain
and infertility. It is characterized by the presence
of endometrial tissue on the outside of the uterus,
most commonly in the pelvic, peritoneum or
ovaries, but can also occur in recto-vaginal septum
and rare in pleural, pericardial or brain. Its
prevalence is estimated to be 6-10% in general
woman population and 35-50% of patients
experience pain and or infertility. The actual
prevalence and incidence of endometriosis in the
general population is not clear. Preciado et al
investigated the infertile woman with endome-
triosis at age 30.3  3.9 years, while the incidence
of endometriosis in 197 infertile women was 68
people (34.5%).1
At the clinical level, endometriosis has a
significant impact on a variety of subjective and
objective changes, especially in terms of pain
(dysmenorrhea, dyspareunia, diskezia), infertility
and menstruation impaired. Social impact of this
disease is the other side need to be considered by
practitioners. Since the etiology and pathogenesis
of endometriosis is still an enigma, the treatment
is still a controversy.
Abstract
Objective: To investigate the role of MMP-9 expression in
endometriosis.
Methods: The study was conducted from October 2015 to March
2016, an observational study with cross-sectional design. Samples
are all endometriosis patients who underwent laparoscopic surgery
in Dr. Wahidin Sudirohusodo Hospital and several other hospitals in
Makassar. Samples were stored and fixed in the Grand Medika
Histopathology Laboratory Makassar for examination the expres-
sion of MMP-9 using immunohistochemical methods. Conducted an
analysis of 50 samples, of which 11 samples of stage II, 21 stage III
samples, and 18 samples of stage IV. The data obtained and analyzed
statistically using Mann Whitney and Chi Square test with a signi-
ficance level of p <0.05.
Results: The results reported rankings mean the expression of
MMP-9 in stage I-II = 16.68, stage III-IV 27.99 (p = 0.013). There
were differences in the expression of MMP-9 based on the stage.
Stage I-II endometriosis had a more positive 2 expression of
MMP-9 (45.5%), stage III-IV endometriosis have more positive 3
expression of MMP-9 (59.0%). The results of chi square test (p =
0.043).
Conclusion: Higher expression of MMP-9 is significantly associated
with higher degree of endometriosis.
[Indones J Obstet Gynecol 2017; 5-4: 203-207]
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Abstrak
Tujuan: Mengetahui peran matriks metalloproteinase-9 (MMP-
9) dengan derajat berat ringannya endometriosis.
Metode: Penelitian dilakukan dari bulan Oktober 2015 sampai Maret
2016, merupakan penelitian observasional dengan desain potonglintang (cross sectional study). Sampel adalah semua penderita
endometriosis yang menjalani operasi laparoskopi di RS Dr. Wahidin
Sudirohusodo dan beberapa rumah sakit lain di Makassar. Sampeldisimpan dan difiksasi pada Laboratorium Histopatologi Grand
Medika Makassar untuk pemeriksaan ekspresi MMP-9 jaringandengan menggunakan metode imunohistokimia. Dilakukan analisis
terhadap 50 sampel, di mana 11 sampel stadium II, 21 sampel stadium
III, dan 18 sampel stadium IV. Data yang diperoleh kemudian diana-lisa statistik menggunakan uji Mann Whitney dan uji Chi Square
dengan tingkat kemaknaan p<0,05.
Hasil: Penelitian menunjukkan Rerata rangking ekspresi MMP-9
pada stadium I-II = 16,68, stadium III-IV 27,99 (p = 0,013). Stadiumendometriosis I-II lebih banyak mempunyai ekspresi MMP-9 positif
2 (45,5%), stadium endometriosis III-IV lebih banyak mempunyai
ekspresi MMP-9 positif 3 (59,0%).
Kesimpulan: Ekspresi MMP-9 berkaitan dengan derajat keparahan
endometriosis.
[Maj Obstet Ginekol Indones 2017; 5-4: 203-207]
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Endometriosis is accompanied by increased
secretion of pro-inflammatory cytokines, impaired
cell-mediated immunity, neo-angiogenesis and
endometrial reflux anomalies. To date, many of
analysis of cytokines have been done thought to be
involved in endometriosis. Many factors contribute
to triggering, one of them is a metalloproteinase
matrix (MMP), a family of zinc-dependent
endopeptidase that regulate the integrity and
composition of the extracellular matrix. MMP
plays an important role in cell proliferation,
migration, differentiation, angiogenesis, apoptosis,
and immune system. Dysregulation of MMP has
implications in various diseases including tumor
growth. The initial phase of endometriosis is the
degradation and remodeling of the extracellular
matrix and increased expression of MMP.2
Among the various MMP, found over-expression
of metalloproteinase-9 matrix (MMP-9) in different
types of tumor. In mouse model, found the role of
MMP-9 in terms of the process of invasion,
aggression, and tumor metastases.3 High
expression of MMP-9 is an indicator of the
progression of tumor growth, reduced survival
rate, and increased metastases.
The previous studies evaluating the role of MMP
in endometriosis had been done with different
techniques and materials. Increased expression
of MMP-9 was higher in ectopic endometrium
(endometriosis) than eutopic endometrium and
higher in severe endometriosis.4,5 However, the
study of the role of MMP-9 as endometriosis
marker still less common in Indonesia, especially
in South Sulawesi.
This study aimed to evaluate the correlation
between the expression of Metalloproteinase
Matrix-9 (MMP-9) and the severity of endo-
metriosis.
METHODS
This was a cross-sectional study. This study
was conducted at several teaching hospitals in
Makassar, South Sulawesi, including Dr. Wahidin
Sudirohusodo Hospital and other private hospitals
used as the teaching hospital networking. The
tissue samples of endometriosis cyst that had been
fixed were kept at Histopathology Laboratory
Grand Medika Makassar for examination the
expression of MMP-9. This study was conducted
from October 2015 to March 2016. Samples were
all patients with endometriosis who underwent
laparoscopic surgery. Data were analyzed using
Mann Whitney and Chi Square test. P values less
than 0.05 were considered as statistically
significant.
RESULTS
Table 1 shows the characteristics of the patients.
Majority of the patients were in stage III-IV of
endometriosis (78%), while stage I-II of 22%. The
percentage of women who experienced dysme-
norrhea were 54%, a history of infertility (56%),
the age of older 35 years old (56%), married
(92%), normal weight (56%) and did not use
contraception (82%).
Table 1. The Characteristics of the Patients.
Characteristics Amount(n)
Percentage
(%)
Stage of Endometriosis
I - II 11 22
III - IV 39 78
Dysmenorrhea
Yes 27 54
No 23 46
Infertile
Yes 28 56
No 22 44
Age Group
 35 22 44
> 35 28 56
Marital Status
Yes 46 92
No 4 8
BMI
Normoweight 28 56
Overweight 22 44
Contraception
Yes 9 18
No 41 82
Table 2 shows the stages of endometriosis based
on the characteristics of the patients. Most of the
patients stage I-II endometriosis may experience
more dysmenorrhea (63.6%), infertility (72.7%),
the age of less than or equal to 35 years old
Indones J
204  Amalia et al Obstet Gynecol
(54.5%), married (90.9%), normal weight (72.7%)
and did not use contraception (100%). Patients
stage III-IV endometriosis may experience more
dysmenorrhea (51.3%), infertility (51.3%), the age
of older 35 years old (59.0%), married (92.3%),
normal weight (51.3%) and did not use contra-
ception (76.9%).
Table 2. Stages of Endometriosis Based on the Charac-
teristics of the Patient.
Characteristics
I­II III­IV
n % n % Amount %
Dysmenorrhea
Yes 7 63.6 20 51.3 27 54
No 4 36.4 19 48.7 23 46
Infertile
Yes 8 72.7 20 51.3 28 56
No 3 27.3 19 48.7 22 44
Age Group
 35 6 54.5 16 41.0 22 44
> 35 5 45.5 23 59.0 28 56
Marital Status
Yes 10 90.9 36 92.3 46 92
No 1 9.1 3 7.7 4 8
BMI
Normoweight 8 72.7 20 51.3 28 56
Overweight 3 27.3 19 48.7 22 44
Contraception
Yes - - 9 23.1 9 18
No 11 100.0 30 76.9 41 82
Table 3 shows the differences between the
average ranking of expression of MMP-9 based on
the stage of endometriosis. The average ranking of
the expression of MMP-9 in stage I-II was 11.36,
stage III-IV of 29.49. Statistical test results obtained
by Mann Whitney, p value = 0.000. It is suggested
that there are differences in the expression of
MMP-9 based on the stage, where the higher stages
of endometriosis, then the higher the expression of
MMP-9.
Table 3. The Differences between the Average Ranking of
Expression of MMP-9 Based on the Stage of Endometriosis
Stage of
Endometriosis
The Average Ranking Of
MMP­9
Significance
(p)
Stage I-II 16.68 0.013
Stage III-IV 27.99
Table 4 shows the association between the stage
of endometriosis and the expression of MMP-9. The
Patients who had stage I-II endometriosis have
more expression of MMP-9 positive 2 (45.5%),
stage III-IV endometriosis have more expression of
MMP-9 positive 3 (59.0%). The result of Chi Square
test was obtained value p = 0.043. This suggested
that there is an association between the stage of
endometriosis and the expression of MMP-9.
Table 4. The Association between the Stage of Endome-
triosis and the Expression of MMP-9.
MMP­9
Expression
Stage of Endometriosis Significant
(p)
I­II III­IV Total
n % n % n %
Positive 1 4 36.4 5 12.8 9 18.0 0.043
Positive 2 5 45.5 11 28.2 16 32.0
Positive 3 2 18.2 23 59.0 25 50.0
Total 11 100.0 39 100.0 50 100.0
DISCUSSION
The study showed an increased expression of
MMP-9 in the tissue and parallel with increasing
the stage of endometriosis. More than 10% of
women have endometriosis. Most of them have no
or only little complains of symptoms, thus the
prevalence of severe endometriosis (stage III-IV)
more than mild endometriosis (stage I-II). Some
women complain of severe dysmenorrhea, chronic
pelvic pain, and dyspareunia. Symptoms depend on
the location, distribution, and depth of endome-
trium implantation, the presence and severity of
adhesions, the presence and size of ovarian
endometrioma. A study by Ragab et al involving
654 young adult women with endometriosis found
that 48.9% of the subjects complained menstrual
pain, and 68.8% reporter severe dysmenorrhoea.6
A retrospective study by Andres et al involving
394 patients showed that dysmenorrhoea
affects 80.9% young adult patients (severe dys-
menorrhoea of 33.3%) and chronic pelvic pain
of 66.6%.7
The mean age of patients with endometriosis
varies 31.1  10.4 years (between 17-53 years old),
mostly 30-35 years.8 According to the theory, the
true prevalence of endometriosis is unknown, but
approximately 5-10% of women in reproductive
age (menarche to menopause). The peak age is 25-
Vol 5, No 4
October 2017 The Role of MMP-9 in Endometriosis  205
30 years old, and is rare in young women or post-
menopausal women.
Macer et al revealed that women with mild en-
dometriosis showed a decrease in the pregnancy
rate after 3 years compared to women with un-
explained infertility (36 vs 55%).9 Brosens et al
conducted a study of IVF, and they concluded that
in women with severe endometriosis, decreased
ovarian reserve, decreased embryo quality and
total of oocytes, and decreased the implantation
ratio. The correlation between endometriosis and
infertility is supported by the literature.10
The study by Yi et al, including 481 women with
endometriosis, stage I by 153 women, stage II by
113, stage III by 110, and stage IV by 105, showed
that women with severe stage (III-IV) were
associated with low BMI, compared to patients
with minimal or mild stage (I-II), and BMI was
significantly related to the stage of disease.11
In this study, there was significant association
between the expression of MMP-9 based on the
stage of endometriosis, where the higher stages of
the disease, the higher the expression of MMP-9.
The immunohistochemical study of 20 cases with
endometriosis showed that MMP-1, -2, and -9 were
strongly detected in the stroma and epithelial
cells.12 This study supported by Chen et al,
showed that increased MMP-9 occurred in ectopic
endometrium. Collette et al. revealed that in-
creased proteolytic activity of eutopic endome-
trium occurred in women with endometriosis than
normal women, where found an increase in MMP-9
and a decrease in its natural inhibitor.13
T h e  p a t h o g e n e s i s  o f  e n d o m e t r i o s i s
regarding attachment-aggression-angiogenesis (AAA)
scheme has been generally accepted. In this
process, the role of MMP was uncontested. MMP is
a family of zinc-dependent endopeptidase that can
degrade extracellular collagen and matrix
components. The formation of ectopic endometrial
tissue mediated by factors that facilitate adhesion
to peritoneal cavity include cell growth, increased
aromatase activity, angiogenic, neuralgenic/
lymphogenic factors, and reinforced by the activity
of MMP. MMP regulated migration, infiltration,
proliferation and apoptosis of cells. MMP-2 and
MMP-9 are two members of the MMP family that
is the most powerful in degrading collagen IV.
In order to occurred adhesion and infiltration,
structural changing should be occurred in the
tissue by the extracellular membrane degradation
a n d  M M P  p l a y  a  r o l e  i n  a c c e l e r a t i n g
neovascularization.13,14
Swarnakar et al stated that the synthesis of
MMP-9 was correlated positively to the stage of
the disease, where a correlation between focal
inflammatory pelvic endometriosis was found, as
consequence found improved functioning of
immune cells in the peritoneal cavity.15 MMP-9 is
mainly synthesized and secreted by macrophages
and neutrophils.16 In peritoneal fluid, found a large
number of derivate-macrophages substance,
resulting in increased levels of MMP-9 in the
peritoneal fluid of patients with endometriosis, in
line with the severity of the stadium. Once ectopic
endometrium was implanted in the peritoneum, a
large number of MMP was expressed by autocrine
and paracrine cytokine activation, thereby in-
creasing the extracellular matrix degradation that
contribute to further growth of the endometrium.
This is also consistent with a recent study by Liu
et al, involving 100 patients with endometriosis,
including ectopic endometrium and eutopic endo-
metrium, and patients with uterine myoma as
controls. Blood and acites fluid sampling were
performed to evaluate the level of MMP-9 using
zimogram and enzyme-linked immunosorbent
assay (ELISA). The results showed a significant
correlation between MMP-9 and the location of the
endometrium, clinical stage, and the proliferation
cycle (p <0.005).4
The different result reported by Gilabert-
Estelles et al, that get the unsignificant expression
of MMP-9 in the immunohistochemical exami-
nation of endometrial and ovarian tissue of en-
dometriosis patients, the study revealed a new
theory that the activity of proteolytic enzymes such
as protease and gelatinase (MMP 2 and MMP-9) is
likely to be only increased in the early formation
of endometriosis implants, but when cysts/
endometrioma formed, proteolytic activity was not
found anymore, only the levels of inhibitors such
as PAI-1 and TIMP-1 is relatively increased,
although not in all cases. These findings may
elucidate the operative clinical implications where
endometrioma cysts are often found in the absence
of adhesions and expansion into the surrounding
tissue of the ovary.17
CONCLUSIONS
We found that higher MMP-9 expression is asso-
ciated with higher degree of endometriosis.
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